Complexa’s platform is based on differentiated endogenous Nitro Fatty Acid (NFA) and Keto Fatty Acid (KFA) Anti-Fibrosis and Anti-Inflammation Cell Signaling Technology.
Complexa’s lead compound Oral CXA-10 (10-nitro-oleic-acid) is scheduled to begin Phase 2 clinical development for the treatment of two orphan diseases in 2017. These include Focal Segmental Glomerulosclerosis (FSGS) and Pulmonary Arterial Hypertension (PAH). Complexa’s platform also includes additional preclinical nitro and fatty acid compounds planned for oral orphan indications.
- Extensive and compelling preclinical and clinical safety and biomarker data from 5 Phase 1 trials in over 100 subjects
- Phase 2 Proof Of Concept FSGS in 2017
- Phase 2 Proof Of Concept PAH in 2017
Preclinical Nitro and Keto Fatty Acid Compounds:
- Complexa is advancing a pipeline of additional nitro fatty acids and keto fatty acids with IND enabling programs.
omplexa has developed a diverse patent portfolio around lead compounds and their related drug classes. In addition to the company’s own portfolio, Complexa has formed license agreements with three universities, each prominent in the field of anti-inflammatory cell signaling research. Complexa’s strong and visionary IP position provides the company with a solid proprietary intellectual property positions in compositions of matter, methods of use, and others.